Multispecific Antibodies Targeting HLA-A2/MAGE-A4 Cancer Therapy

Fri, 10 Apr 2026 01:20:46 +0000
Pharmaceuticals

USPTO published Roche/Genentech patent application US20260098095A1 disclosing multispecific antibodies binding to HLA-A2/MAGE-A4 complex for T cell activation in cancer treatment. The application covers antibody compositions, encoding polynucleotides, production methods, and therapeutic uses. The invention addresses immunotherapy approaches for HLA-A2-positive tumors expressing MAGE-A4 antigen.